PMID- 14583236
OWN - NLM
STAT- MEDLINE
DCOM- 20031218
LR  - 20191108
IS  - 0889-1591 (Print)
IS  - 0889-1591 (Linking)
VI  - 17
IP  - 6
DP  - 2003 Dec
TI  - Neuropeptide specificity of prostaglandin E2-induced activation of splenic and 
      renal sympathetic nerves in the rat.
PG  - 442-52
AB  - Sympathetic activation occurs rapidly following intracerebroventricular (icv) 
      injection of prostaglandin E2(PGE2). This study examined whether neuropeptides 
      mediate PGE2-induced sympathetic nerve activation in 
      urethane/chloralose-anesthetized Sprague-Dawley rats. Animals were pretreated 
      (20.0 microg, icv) with the following receptor antagonists; CRF 
      ([D-Phe12,Nle21,38,Calpha-MeLeu37]CRF12-41), AVP-V1 (Des-Gly-[Phaa1, 
      D-Tyr(Et)2,Lys6,Arg8]-vasopressin), or OT (OT+V1, 
      [d(CH2)5,Tyr(Me)2,Orn8]-vasotocin) followed 20 min later by PGE2 (2.0 microg, 
      icv). Pretreatment with the CRF antagonist attenuated the increase in renal nerve 
      activity induced by PGE2 when measured 10 and 30 min post-injection. PGE2-induced 
      renal nerve activity was also inhibited at both time points by the AVP antagonist 
      and, to a similar extent, the OT antagonist. The AVP antagonist did not effect 
      splenic nerve responses to PGE2 whereas the CRF antagonist produced an incomplete 
      and transient reduction in PGE2-induced activation of the splenic nerve. However, 
      the OT antagonist completely blocked the activation of the splenic nerve after 
      central injection of PGE2. ICV injections of AVP and OT produced immediate 
      changes in splenic and renal nerve activity whereas CRF failed to alter the 
      activity of either nerve in anesthetized or conscious animals. Thus, PGE2 acts 
      through neuropeptide-specific pathways to initiate sympathetic outflow and OT is 
      a specific component of the sympathetic pathway innervating the spleen.
FAU - MacNeil, Brian J
AU  - MacNeil BJ
AD  - School of Medical Rehabilitation, University of Manitoba, R106-771 McDermot 
      Avenue, Winnipeg, Man., Canada R3E 0T6. macniel@scrc.umanitoba.ca
FAU - Jansen, Arno H
AU  - Jansen AH
FAU - Greenberg, Arnold H
AU  - Greenberg AH
FAU - Nance, Dwight M
AU  - Nance DM
LA  - eng
GR  - MH-43778-04A2/MH/NIMH NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Netherlands
TA  - Brain Behav Immun
JT  - Brain, behavior, and immunity
JID - 8800478
RN  - 0 (Antidiuretic Hormone Receptor Antagonists)
RN  - 0 (Hormone Antagonists)
RN  - 0 (Receptors, Corticotropin-Releasing Hormone)
RN  - 0 (Receptors, Oxytocin)
RN  - K7Q1JQR04M (Dinoprostone)
SB  - IM
MH  - Animals
MH  - Antidiuretic Hormone Receptor Antagonists
MH  - Brain/physiology
MH  - Dinoprostone/administration & dosage/*physiology
MH  - Hormone Antagonists/pharmacology
MH  - Injections, Intraventricular
MH  - Kidney/*innervation
MH  - Male
MH  - Neuroimmunomodulation/drug effects/*physiology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Receptors, Corticotropin-Releasing Hormone/antagonists & inhibitors
MH  - Receptors, Oxytocin/antagonists & inhibitors
MH  - Spleen/*innervation
MH  - Sympathetic Nervous System/drug effects/*physiology
EDAT- 2003/10/30 05:00
MHDA- 2003/12/19 05:00
CRDT- 2003/10/30 05:00
PHST- 2003/10/30 05:00 [pubmed]
PHST- 2003/12/19 05:00 [medline]
PHST- 2003/10/30 05:00 [entrez]
AID - S0889159103000503 [pii]
AID - 10.1016/s0889-1591(03)00050-3 [doi]
PST - ppublish
SO  - Brain Behav Immun. 2003 Dec;17(6):442-52. doi: 10.1016/s0889-1591(03)00050-3.